U.S. Androgenetic Alopecia Market Size, Share & Trends Analysis Report By Treatment (Pharmaceuticals, Devices), By Sales Channel (Prescriptions, OTC), By Gender, By End Use, And Segment Forecasts, 2025 - 2030

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
  • 1.2.3. Sales Channel
  • 1.2.4. Gender
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Sales Channel Outlook
  • 2.2.4. Gender Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Androgenetic Alopecia Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. U.S. Androgenetic Alopecia Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape
• 3.4. U.S. Androgenetic Alopecia Market: Pipeline Analysis

Chapter 4. U.S. Androgenetic Alopecia Market: Treatment Estimates & Trend Analysis

• 4.1. Treatment Segment Dashboard
• 4.2. U.S. Androgenetic Alopecia Market: Treatment Movement Analysis
• 4.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
• 4.4. Pharmaceuticals
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Devices
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Androgenetic Alopecia Market: End Use Estimates & Trend Analysis

• 5.1. End Use Segment Dashboard
• 5.2. U.S. Androgenetic Alopecia Market: End Use Movement Analysis
• 5.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 5.4. Homecare Settings
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Dermatology Clinics
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Androgenetic Alopecia Market: Sales Channel Estimates & Trend Analysis

• 6.1. Sales Channel Segment Dashboard
• 6.2. U.S. Androgenetic Alopecia Market: Sales Channel Movement Analysis
• 6.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
• 6.4. Prescriptions
  • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD million)
• 6.5. OTC
  • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Androgenetic Alopecia Market: Gender Estimates & Trend Analysis

• 7.1. Male
  • 7.1.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.2. Female
  • 7.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company heat map analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Johnson & Johnson Services, Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Cipla
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Sun Pharmaceutical Industries Ltd.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Merck & Co., Inc
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Dr. Reddy's Laboratories Ltd.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Aurobindo Pharma Limited
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Hairmax International LLC
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Curallux, LLC
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Apira Science, Inc. (iGROW Laser)
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. Theradome Inc.
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 3 U.S. androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 4 U.S. androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 5 U.S. androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. androgenetic alopecia market: market outlook
• Fig. 10 U.S. androgenetic alopecia competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 U.S. androgenetic alopecia market driver impact
• Fig. 16 U.S. androgenetic alopecia market restraint impact
• Fig. 17 U.S. androgenetic alopecia market strategic initiatives analysis
• Fig. 18 U.S. androgenetic alopecia market: Treatment movement analysis
• Fig. 19 U.S. androgenetic alopecia market: Treatment outlook and key takeaways
• Fig. 20 Pharmaceuticals market estimates and forecast, 2018 - 2030
• Fig. 21 Devices market estimates and forecast, 2018 - 2030
• Fig. 22 U.S. androgenetic alopecia market: End Use movement analysis
• Fig. 23 U.S. androgenetic alopecia market: End Use outlook and key takeaways
• Fig. 24 Homecare settings market estimates and forecasts, 2018 - 2030
• Fig. 25 Dermatology clinics market estimates and forecasts, 2018 - 2030
• Fig. 26 U.S. androgenetic alopecia market: Sales channel movement analysis
• Fig. 27 U.S. androgenetic alopecia market: Sales channel outlook and key takeaways
• Fig. 28 Prescriptions market estimates and forecasts, 2018 - 2030
• Fig. 29 OTC market estimates and forecasts, 2018 - 2030
• Fig. 30 U.S. androgenetic alopecia market: Gender movement analysis
• Fig. 31 U.S. androgenetic alopecia market: Gender outlook and key takeaways
• Fig. 32 Male market estimates and forecasts, 2018 - 2030
• Fig. 33 Female market estimates and forecasts, 2018 - 2030